Brought to you by 
Janssen Pharmaceuticals gets rights to Shionogi's BACE inhibitors for Alzheimer's disease
27 Apr 2018
Executive Summary
Johnson & Johnson’s Janssen Pharmaceuticals Inc. has licensed exclusive rights to Shionogi & Co. Ltd.’s oral preclinical beta secretase (BACE) inhibitors for Alzheimer’s disease.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen Pharmaceuticals gets rights to Shionogi's BACE inhibitors for Alzheimer's disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice